The extended follow-up data significantly de-risks the BLA submission and approval odds. Traders should monitor for FDA acceptance of the BLA in late 2026 and potential priority review. Given CADL's small market cap ($653M), positive regulatory milestones could drive substantial upside.
Price Chart
Executive Summary
Candel Therapeutics announced extended follow-up data from the phase 3 trial of aglatimagene (CAN-2409) in localized prostate cancer, showing a statistically significant 39% improvement in prostate cancer-specific disease-free survival (HR 0.61, p=0.0031) at a median follow-up of 58 months. The company plans to submit a BLA to the FDA in Q4 2026, representing a major derisking event for this lead asset.
Key Facts
- 39% improvement in prostate cancer-specific DFS vs placebo (HR 0.61, 95% CI 0.44-0.85, p=0.0031) at median 58-month follow-up.
- In intermediate-risk subgroup (85% of patients), 90% improvement in time to metastasis (HR 0.1, 95% CI 0.01-0.85).
- BLA submission planned for Q4 2026; prior Fast Track and RMAT designations granted.
- Over 1,000 patients dosed with aglatimagene with favorable tolerability profile; no new safety signals.
Financial Impact
If approved, aglatimagene could become the first new therapy for localized prostate cancer in over 20 years, addressing a ~30% recurrence rate within 10 years on current SOC. Peak sales potential could exceed $1B, but no specific estimates provided.
Risk Factors
- BLA submission and eventual FDA approval are not guaranteed; regulatory risks remain.
- Data from the open-label phase 3 (already positive) is now reinforced, but long-term overall survival data is immature.
- Competition from existing therapies (radiation, surgery, active surveillance) and potential new entrants.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296125 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | Press Release | $10.16 | awaiting T+60 | — | $7.79 (−23.33%) |
Sep 30, 2026 26d ago | Press Release | $10.44 | awaiting T+60 | — | $7.79 (−25.38%) |
Sep 10, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Sep 9, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Aug 15, 2026 10w ago | Institutional Cluster | $12.16 | awaiting T+60 | — | $7.79 (−35.94%) |
Aug 13, 2026 10w ago | 8-K | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 13, 2026 10w ago | Press Release | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 3, 2026 12w ago | Press Release | $10.07 | awaiting T+60 | — | $7.79 (−22.64%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers